Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_assertion type Assertion NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_head.
- NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_assertion description "[Indeed, the BCR-ABL1 fusion product is a target against which many tyrosine kinase inhibitors (TKIs) have been proven to be effective in the treatment of CML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_provenance.
- NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_assertion evidence source_evidence_literature NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_provenance.
- NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_assertion SIO_000772 23412783 NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_provenance.
- NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_assertion wasDerivedFrom befree-2016 NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_provenance.
- NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_assertion wasGeneratedBy ECO_0000203 NP1053246.RAI8weow6RDpd7oOep6VHBz7CW9oYxCdZugzVt20SsQJM130_provenance.